Shandong Weigao Blood Valuation Multiples

Discover revenue and EBITDA valuation multiples for Shandong Weigao Blood and similar public comparables like BioLife Solutions, Dentsply Sirona, Chengzhi, Kestra Medical Technologies and more.

Shandong Weigao Blood Overview

About Shandong Weigao Blood

Shandong Weigao Blood Purification Products Co Ltd engaged in research and development, production and sales of blood purification medical products.


Founded

2004

HQ

China

Employees

N/A

Financials (LTM)

Revenue: $589M
EBITDA: $128M

EV

$1.6B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Shandong Weigao Blood Financials

Shandong Weigao Blood reported last 12-month revenue of $589M and EBITDA of $128M.

In the same LTM period, Shandong Weigao Blood generated $235M in gross profit, $128M in EBITDA, and $75M in net income.

Revenue (LTM)


Shandong Weigao Blood P&L

In the most recent fiscal year, Shandong Weigao Blood reported revenue of $561M and EBITDA of $122M.

Shandong Weigao Blood is profitable as of last fiscal year, with gross margin of 40%, EBITDA margin of 22%, and net margin of 13%.

See analyst estimates for Shandong Weigao Blood
LTMLast FY202320242025202620272028
Revenue$589M$561M$524M$534M$561M
Gross Profit$235M$226M$229M$226M$226M
Gross Margin40%40%44%42%40%
EBITDA$128M$122M$113M$117M$122M
EBITDA Margin22%22%22%22%22%
EBIT Margin15%15%15%15%15%
Net Profit$75M$72M$66M$67M$72M
Net Margin13%13%13%12%13%
Net Debt-($235M)---

Financial data powered by Morningstar, Inc.

Shandong Weigao Blood Stock Performance

Shandong Weigao Blood has current market cap of $2B, and enterprise value of $1.6B.

Market Cap Evolution


Shandong Weigao Blood's stock price is $4.76.

Shandong Weigao Blood share price decreased by 0.1% in the last 30 days, and by 12.7% in the last year.

Shandong Weigao Blood has an EPS (earnings per share) of $0.17.

See more trading valuation data for Shandong Weigao Blood
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$1.6B$2B-1.7%-0.1%-9.1%-12.7%$0.17

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Shandong Weigao Blood Valuation Multiples

Shandong Weigao Blood trades at 2.7x EV/Revenue multiple, and 12.3x EV/EBITDA.

See NTM and 2027E valuation multiples for Shandong Weigao Blood

EV / Revenue (LTM)


Shandong Weigao Blood Financial Valuation Multiples

As of August 25, 2026, Shandong Weigao Blood has market cap of $2B and EV of $1.6B.

Shandong Weigao Blood has a P/E ratio of 26.6x.

LTMLast FY202320242025202620272028
EV/Revenue2.7x2.8x3.0x2.9x2.8x
EV/EBITDA12.3x12.9x13.9x13.5x12.9x
EV/EBIT17.4x19.0x20.5x19.1x19.0x
EV/Gross Profit6.7x7.0x6.9x7.0x7.0x
P/E26.6x27.7x30.3x29.8x27.7x
EV/FCF-16.7x191.9x27.0x16.7x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Shandong Weigao Blood Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Shandong Weigao Blood Margins & Growth Rates

Shandong Weigao Blood grew revenue by 9% and EBITDA by 8% in the last fiscal year.

In the most recent fiscal year, Shandong Weigao Blood reported gross margin of 40%, EBITDA margin of 22%, and net margin of 13%.

See estimated margins and future growth rates for Shandong Weigao Blood

Shandong Weigao Blood Margins

Last FY202420252026202720282029
Gross Margin40%42%40%40%
EBITDA Margin22%22%22%22%
EBIT Margin15%15%15%15%
Net Margin13%12%13%13%
FCF Margin17%11%17%-

Shandong Weigao Blood Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth9%2%5%9%
Gross Profit Growth8%(1%)(0%)8%
EBITDA Growth8%3%5%8%
EBIT Growth13%7%0%13%
Net Profit Growth8%2%8%8%
FCF Growth-610%62%-

Data powered by FactSet, Inc. and Morningstar, Inc.

Shandong Weigao Blood Operational KPIs

Shandong Weigao Blood's Rule of 40 is 31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Shandong Weigao Blood's Rule of X is 45% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Shandong Weigao Blood
LTMLast FY202320242025202620272028
Rule of 4032%31%---
Bessemer Rule of X48%45%---
S&M Expenses to Revenue17%9%23%10%9%
G&A Expenses to Revenue5%1%3%2%1%
R&D Expenses to Revenue4%4%4%5%4%
Opex to Revenue-25%29%27%25%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Shandong Weigao Blood Competitors

Shandong Weigao Blood competitors include BioLife Solutions, Dentsply Sirona, Chengzhi, Kestra Medical Technologies, Inner Mongolia Furui Medical Science, Sopharma, Gerresheimer, Shinva, Menicon and Ansell.

Most Shandong Weigao Blood public comparables operate across Medical Supplies.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
BioLife Solutions18.2x16.2x(173.5x)62.6x
Dentsply Sirona1.2x1.2x(92.3x)6.6x
Chengzhi1.3x1.3x16.6x-
Kestra Medical Technologies15.0x13.1x(11.5x)(16.4x)
Inner Mongolia Furui Medical Science6.2x6.4x22.8x27.8x
Sopharma1.0x-10.7x-
Gerresheimer1.3x1.3x60.6x7.4x
Shinva0.6x0.6x6.8x6.9x

This data is available for Pro users. Sign up to see all Shandong Weigao Blood competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Shandong Weigao Blood

When was Shandong Weigao Blood founded?Shandong Weigao Blood was founded in 2004.
Where is Shandong Weigao Blood headquartered?Shandong Weigao Blood is headquartered in China.
Is Shandong Weigao Blood publicly listed?Yes, Shandong Weigao Blood is a public company listed on Shanghai Stock Exchange.
What is the stock symbol of Shandong Weigao Blood?Shandong Weigao Blood trades under 603014 ticker.
When did Shandong Weigao Blood go public?Shandong Weigao Blood went public in 2025.
Who are competitors of Shandong Weigao Blood?Shandong Weigao Blood main competitors include BioLife Solutions, Dentsply Sirona, Chengzhi, Kestra Medical Technologies, Inner Mongolia Furui Medical Science, Sopharma, Gerresheimer, Shinva, Menicon, Ansell.
What is the current market cap of Shandong Weigao Blood?Shandong Weigao Blood's current market cap is $2B.
What is the current revenue of Shandong Weigao Blood?Shandong Weigao Blood's last 12 months revenue is $589M.
What is the current revenue growth of Shandong Weigao Blood?Shandong Weigao Blood revenue growth (NTM/LTM) is 10%.
What is the current EV/Revenue multiple of Shandong Weigao Blood?Current revenue multiple of Shandong Weigao Blood is 2.7x.
What is the current EBITDA of Shandong Weigao Blood?Shandong Weigao Blood's last 12 months EBITDA is $128M.
What is Shandong Weigao Blood's EBITDA margin?Shandong Weigao Blood's last 12 months EBITDA margin is 22%.
What is the current EV/EBITDA multiple of Shandong Weigao Blood?Current EBITDA multiple of Shandong Weigao Blood is 12.3x.
How many companies Shandong Weigao Blood has acquired to date?Shandong Weigao Blood hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Shandong Weigao Blood has invested to date?Shandong Weigao Blood hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Shandong Weigao Blood

Lists including Shandong Weigao Blood

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial